1-4 of 4
David J Curtis
Close
Sort by
Journal Articles

Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis

Clinical Trials & Observations
Jasmine Singh, Nancy Li, Elham Ashrafi, Le Thi Phuong Thao, David J. Curtis, Erica M. Wood, Zoe K. McQuilten
Journal: Blood Advances
Blood Adv (2024) 8 (14): 3771–3784.
https://doi.org/10.1182/bloodadvances.2024013228
Published: 2024
Includes: Supplemental data
Journal Articles

Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia

Stien De Coninck, Juliette Roels, Béatrice Lintermans, Sara T’Sas, Tom Taghon, David J. Curtis, Tim Pieters, Steven Goossens, Pieter Van Vlierberghe
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2646–2649.
https://doi.org/10.1182/bloodadvances.2023011970
Published: 2024
Includes: Supplemental data
Journal Articles

Variable CD34 + recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Duncan Purtill, Vicki Antonenas, Paul Chiappini, Daochen Tong, Elizabeth O’Flaherty, Ashish Bajel, Karieshma Kabani, Stephen Larsen, Suikeat Tan, Cheryl Hutchins, David J. Curtis, Glen A. Kennedy, Anne-Marie Watson, LiJun Bai, Matthew Greenwood, David J. Gottlieb, Nada Hamad
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4147–4150.
https://doi.org/10.1182/bloodadvances.2020002431
Published: 2020
Includes: Supplemental data
Journal Articles

Characterization of Tfrc -mutant mice with microcytic phenotypes

Ashlee J. Conway, Fiona C. Brown, Gerhard Rank, Benjamin T. Kile, Craig J. Morton, Stephen M. Jane, David J. Curtis
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1914–1922.
https://doi.org/10.1182/bloodadvances.2018018820
Published: 2018